Innovation Tracking in Pharma
Anticipate competitor innovation before it shows up in press releases.
A live framework for tracking innovation in pharma — patents, publications, conference data, deals and talent flow — for competitive and strategy teams.
"How do we see competitor innovation coming before it surfaces publicly?"
Innovation surfaces first in patents, publications, conference abstracts and talent flow — not press releases. A live tracker on these signals gives a 12–24 month lead on competitive moves.
Innovation surfaces in patents, publications, conference data and talent flow long before press releases. Teams that operate live trackers on these signals consistently anticipate competitor moves by 12–24 months.
What we’re seeing in the data.
Patents are the earliest signal
Patent filings precede public asset disclosure by 12–36 months.
Conference data is reliable
ASCO, ESMO, ASH and AHA reveal late-stage trial intent and direction.
Talent flow signals platform building
Senior hires in modality-specific roles (gene editing, ADC) precede platform deals.
Publication patterns are predictive
Surge of company-affiliated publications in a TA precedes pipeline build.
How to think about it.
-
01
Track patents continuously
WIPO, USPTO, EPO with TA + sponsor filters.
-
02
Monitor publications
PubMed, conference abstracts, society journals.
-
03
Map deal pattern
Licensing, partnership, M&A signals.
-
04
Track talent flow
LinkedIn, public job posts, industry hiring.
-
05
Synthesize quarterly
Cross-signal fusion into competitor intelligence.
What separates a good answer from a defensible one.
Most patents and pubs are noise — use sponsor and topic filters aggressively.
Talent moves don’t always indicate strategy; cross-validate with deal data.
Conference disclosures can predict press by 1–2 quarters.
Patent disputes signal strategic intent and risk.
Where the signal comes from.
Common questions.
Which signal is most predictive?
Patents + senior talent moves combined are the strongest leading indicator.
Do we need AI for this?
Yes — manual tracking misses 70% of meaningful signals at TA scale.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist